Similarly, one recent study reported that the PD1 inhibitor, pembrolizumab, achieved complete remission or partial remission in 25% of patients with B-cell lymphoma refractory to and/or relapsed after CD19 CAR T cells treatment. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.